The therapeutic vaccine will be based on Gritstone Oncology’s technology and will use antigens from Gilead Sciences. It’s the latest in a string of partnerships Gilead has signed in its search for an HIV cure.
The company published data in Nature Biotechnology comparing the ability of its EDGE platform to detect neoantigens to those of industry-standard methods.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Gritstone Oncology launched in late 2015, with a $102 million Series A that hinted at some lofty goals for cancer immunotherapy. Some 18-months later, it's presenting the first of its data at the American Association for Cancer Research (AACR) annual meeting.